Clinical Trial

A Study of RJMty19 in Refractory Systemic Lupus Erythematosus (SLE)

Name: A Study of RJMty19 in Refractory Systemic Lupus Erythematosus (SLE) — clinical trial record (NCT06340490)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

This study is an open-label, single-arm, dose escalation and dose expansion study to evaluate the safety, maximum tolerated dose, pharmacokinetic characteristics of allogeneic CD19-CAR-DNT cells (RJMty19) after infusion, and preliminary efficacy in systemic lupus erythematosus (SLE) subjects.

Trial Details

NCT Number	NCT06340490
Lead Sponsor	Guangdong Ruishun Biotech Co., Ltd Collaborators: RenJi Hospital, Peking University People's Hospital, Changhai Hospital, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Conditions	Systemic Lupus Erythematosus
Enrollment	24 participants
Start Date	2024-05-15
Primary Completion	2026-12-31 (estimated)
Study Completion	2027-12-31 (estimated)
Updated on ClinicalTrials.gov	2024-04-01